60 Degrees Pharmaceuticals, Inc. (SXTP)

0.2731 -0.0087 (-3.09%) At close: 04:00PM EDT

60 Degrees Pharmaceuticals, Inc.

1025 Connecticut Avenue NW
Suite 1000
Washington, DC 20036
United States
202-327-5422
https://www.60degreespharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Geoffrey Stuart Dow	Chairman, CEO & President	125.56k	N/A	1974
Mr. Tyrone Miller	CFO & Treasurer	135.63k	N/A	1975
Dr. Bryan Smith	Chief Medical Officer	N/A	N/A	1966
Ms. Kristen Landon	Chief Commercial Officer	N/A	N/A	1967
Ms. Jennifer Herz	Director	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Corporate governance

60 Degrees Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.